Orexigen Therapeutics Announces Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Orexigen Therapeutics (OREX) Reports Q2 Loss of $2.00/Share
August 8, 2017 5:34 PM EDTOrexigen Therapeutics (NASDAQ: OREX) reported Q2 EPS of ($2.00), versus ($1.73) reported last year. Revenue for the quarter came in at $23.4 million versus the consensus estimate of $19.14 million.
For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.
... More